trials for triple negative breast cancer and ovarian cancer. Initial clinical trials have in CLL have indicated that GLG Pharma STAT3 inhibitors are very well tolerated and safe. GLG Pharma has also developed a new technology called Gx-C3 which fools cancer cells into behaving in the laboratory as if they were still in the body. This novel laboratory testing coupled with the STAT3 inhibitors will lead to Patient Centered Personalized treatment protocols.

GLG's STAT3 inhibitors reverse resistance in cancer cells of 24 approved oncology drugs and immunotherapy drugs. The lead compound, GLG-302 is being funded by the National Cancer Institute's Prevent Cancer Program to replace Tamoxifen and Raloxifene, currently prescribed to breast cancer patients that initially survive chemotherapy, radiation and surgery for Triple Negative Breast Cancer and HER2 breast cancers. GLG's compound is also in a new patent applied for intravenous formulation as well. The compounds are safe and far less toxic than the alternatives. GLG has a line of repurposed drugs that can be quickly moved to a 505(B)(2) application and one of these drugs is entering Phase 1-2 clinical trials in Poland for TNBC and other metastatic tumors as well. There are 11 repurposed compounds. GLG has 52 New Chemical Entities as well.